Nivolumab-AVD improved PFS versus brentuximab vedotin-AVD in patients with advanced stage HL

Dr Alex Herrera speaks to ecancer about the SWOG S1826 study, a randomised study investigating the efficacy of nivolumab-AVD compared to brentuximab vedotin-AVD in advanced-stage classic Hodgkin lymphoma.

In this study, eligible patients were randomised 1:1 to either 6 cycles of nivolumab-AVD or brentuximab-AVD.

The primary endpoint of the study was progression-free survival with secondary endpoints being overall survival, event-free survival, patient-reported outcomes, and safety.

The primary endpoint of this study was met, showing a superior 1-year progression-free survival of 94% in the nivolumab-AVD arm as opposed to brentuximab-AVD, which yielded 86%.

Dr Herrera says that one of the most important results from this study is that, as opposed to a majority of paediatric patients receiving radiation at the end of their chemotherapy, in this study 6 out of 1,000 received radiation.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php